BackgroundThe purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes.
MethodsWe compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met(+)) and half were not (Met(-): controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined.
ResultsThe incidence of head and neck cancer was 34% lower in the Met(+) cohort than in the Met(-) cohort (adjusted hazard ratio [HR]=0.66; 95% confidence interval [CI]=0.55-0.79). The risks for oropharyngeal cancer (adjusted HR=0.66; 95% CI=0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR=0.50; 95% CI=0.31-0.80) were significantly lower in the Met(+) cohort than in the Met(-) cohort
Head And Neck-Journal For The Sciences And Specialties of The Head And Neck, v.37 n.9, pp.1268-1273